Chronic lymphocytic leukemia (CLL), Non-Hodgkin lymphoma (NHL), Mantle cell lymphoma (MCL), Myeloma
Fluorescence in situ Hybridization (FISH)
2.0 mL (min. 1.0 mL) peripheral blood in sodium heparin preferred, EDTA accepted
1.0 mL (min. 0.5 mL) bone marrow in sodium heparin preferred, EDTA accepted
5 mm^3 fresh tissue or 3.0 mL (min. 2.0 mL) FNA in MPLN RPMI media
Whole blood and bone marrow, ship ambient
Fresh tissue and FNA ship in a Styrofoam container with a cool/refrigerated pack (Do not allow cool pack to directly contact sample)
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells
In a normal cell, the expected pattern is the two orange signal pattern. An abnormal cell has the one orange signal pattern.
Deletion of 13q is found in a wide variety of myeloid and lymphoid malignancies. Among myeloid disorders, deletion 13 is commonly associated with myelodysplastic syndromes, acute myelogenous leukemia and myeloproliferative disorders. The prognostic implications of 13q deletions in myeloid disorders are unclear.
Among lymphoid disorders, deletion 13q is found in chronic lymphocytic leukemia, non-Hodgkin lymphoma and mantle cell lymphoma. More recently, 13q deletion has been identified as a fairly common defect in multiple myeloma. Deletion 13q is the most common deletion in CLL, found in more than 60% of cases by FISH. When it occurs as the sole chromosome abnormality in typical CLL, deletion 13q14 is associated with a good prognosis. In the presence of other chromosome abnormalities, the favorable outcome is diminished. In NHL, deletion 13q is associated with a low rate of complete remission and a shorter survival. In multiple myeloma, deletion of chromosome 13 is associated with a poor response to chemotherapy and a shorter survival
FISH can detect this deletion in either interphase or metaphase cells.